Initial Clinical Experience with a Minute Ventilation Sensing Rate Modulated Pacemaker: Improvements in Exercise Capacity and Symptomatology

A minute ventilation sensing rate modulated pacemaker was implanted in nine patients with bradycardia. Minute ventilation is sensed in this pacemaker by means of a standard bipolar pacing electrode. Compared with exercise in the constant rate ventricular pacing (WI) mode at 1 month after pacemaker implantation, rate responsive pacing resulted in an improvement of exercise capacity of 33 ± 5% (from 437 ± 42 s in the WI mode to 593 ±57 s in the rate modulated mode, P < 0.01, Bruce protocol). This improvement was maintained in the seven patients in whom an exercise test was repeated at 3 months after implantation. The pacing rate was significantly correlated with oxygen consumption (r = 0.8A ± 0.04) and measured minute ventilation (r = 0.76 ± 0.06), Symptomatology in these patients was assessed by means of self-assessment questionnaires in a double blind, randomized cross-over study in which the pacemaker was alternatively programmed into the WI and rate modulated modes. Significant improvements in "shortness of breath" and "energy during daily activities" were documented during rate modulated pacing and "palpitations" and "chest pain" were not worsened. Most patients preferred the rate modulated mode during the study. In conclusion, rate modulated pacing by sensing minute ventilation resulted in better exercise capacity and symptomatology. The pacing rate also showed good correlation with the individual's oxygen requirement.     

Pacemaker Implantation in Children: A 21-Year Experience

Forty-one children, 20 hoys and 21 girls, aged 11 days to 19 years (mean 9.9 years) at initial pacemaker implant, were followed 1 to 248 months (mean 90 months). Ten (mean age 8.2 years) were implanted between 1966 and 1972 (Group I), 14 (mean age 9.9 years) between 1973 and 1980 (Group 11) and 17 (mean age 10.9 years) from 1981 through April 1988 (Group 111). Arrhythmias were congenital complete heart block in 19, postoperative heart block in 15, acquired heart block in 3, sick sinus syndrome in 3, and bradycardia-induced ventricular fibrillation in 1. Twenty-eight of 41 children had a transvenous implant: 40% of Group I, 71% of Group 11 and 82% of Group III. Thirteen were cephalic, four subclavian and 11 jugular. Generator site was pectoral in 19, abdominal in 12, intrathoracic in one, and retromammary in nine of 12 girls aged 10 years or more at implant. In Groups 1,11 and 111, 5, 14 and 6 had VOO or WI units; 5, 0 and 8 dual chamber (VAT, VDD and DDD) pacemakers; 0, 0 and 1 AAI; and 0, 0 and 2 rate-modulated (WIR) units at initial implant. The average interval between pacer-related hospitalizations in Groups I, II and III was 20, 42, and 39 months. Complications included infection in six, hemothorax in one, and impending pacemaker erosion in one. Six patients died, one of pacer infection, four from primary cardiac disease, and one suddenly without apparent reason. Follow-up continues in 31: 14 are employed full-time, three are homemakers, eight are full-time students, and six are active pre-schoolers. Four women have had normal children. We conclude: (1) children with implanted pacemakers can have a normal lifestyle, with prognosis based on underlying cardiac disease; (2) elective epicardial electrodes are now rarely needed; (3) implantation via the cephalic vein is feasible and complication-free; (4) retromammary implant is technically easy and cosmetic; (5) dual chamber and rate-modulated pacemakers can be utilized effectively.(PACE, Vol. 11 November Part II 1988)     

Electrophysiological Demonstration of Anterograde Concealed Conduction in Accessory Atrioventricular Pathways Capable Only of Retrograde Conduction

Anterograde concealed conduction into the concealed accessory atrioventricular (AV) pathway has been postulated to be one of the factors preventing the reciprocating process via the accessory pathway in patients with the concealed Wolff-Parkinson-White(WPW) syndrome but its presence has not been documented. To demonstrate the occurrence of anterograde concealment, 12 patients with the concealed WPW syndrome were selected for study. A pacing protocol was designed in which the retrograde conduction of the ventricular extrastimulus over the accessory pathway was assessed during ventricular pacing aione (conventional method) and during the AV simultaneous pacing (simultaneous method); the results were then compared. When the high right atrium was simultaneously paced, the effective refractory period of the concealed accessory pathway shortened as compared with the conventional method in five of 12 patients (from 341.7 ± 110.8 to 312.5 ± 108.2 msec, n = 12), whereas, it decreased in all patients studied when the coronary sinus near the accessory pathway was simultaneously paced (from 375.7 ± 135.0 to 287. ± 116.1 msec, n = 7). These results demonstrate that the AV simultaneous pacing frequently shortens the refractoriness of the concealed accessory AV pathway and such facilitation seems to he well explained by the probable anterograde concealment in it and peeling back of the refractory barrier.     

Effects of Oral Propafenone Therapy on Chronic Myocardial Pacing Threshold

The effects of oral propafenone therapy on pacing threshold were studied in 36 patients chronically paced for sick sinus syndrome or AV block. The pacemakers, all unipolar models and with noninvasive threshold measurement facilities, were: 9 VVI, 15 AAI, and 12 DDD. Each patient received an initial propafenone dose of 450 mg/day, that in 18 cases was increased to 900 mg/day. Threshold was tested at baseline and at each dosage after 7 days of therapy. With the lower propafenone dosage the threshold, measured at 2.5 V, rose from 0.14 +/- 0.10 to 0.21 +/- 0.16 msec (+55%) in the atrium (P less than 0.0001) and from 0.10 +/- 0.08 to 0.15 +/- 0.09 msec (+63%) in the ventricle (P less than 0.0001). In the 18 patients who received both dosages, the mean atrial and ventricular threshold increased from 0.12 +/- 0.10 to 0.17 +/- 0.14 msec with the lower dose and to 0.27 +/- 0.22 msec (+125%) with the higher dose (P less than 0.0001 for both increments). With the 900 mg/day dose, a threshold increment greater than or equal to 300% was observed in 15% of the stimulated chambers. A good linear correlation (r = 0.76) was found between the ventricular threshold increment and the drug induced QRS widening. In conclusion, treatment with oral propafenone increases atrial and ventricular stimulation threshold in pacemaker patients. Threshold increment is dose dependent and proportional to the drug induced QRS widening. In the majority of the cases the threshold increment is not clinically significant, but caution must be used in prescribing high doses of the drug to patients with high baseline threshold.     

Discrimination of Anterograde From Retrograde Atrial Electrograms for Physiologic Pacing

The morphology of bipolar electrograms recorded in the right atrium was examined in nine patients in an attempt to discriminate retrograde from anterograde atrial signals to an extent that would be useful for physiologic pacing. Peak-to-peak amplitude, duration, square root of energy (energy), maximum slew rate, mean slew rate, and polarity were examined in the time domain. Maximum frequency, half-power frequency, Fourier amplitude peak, and frequency of peak were measured in the frequency domain. There was a significant difference between anterograde and retrograde signals for all variables related to amplitude; these variables are peak-to-peak amplitude, energy, Fourier amplitude peak, maximum slew rate and mean slew rate. In seven of nine patients there was at least one variable sufficiently discriminating to insure reliable detection of anterograde signals while systematically rejecting retrograde signals. However, no individual variable was able to effect this discrimination in more than four patients and at least three variables were needed for all seven patients: maximum frequency, one of either energy and Fourier amplitude peak, and one of either frequency of peak or half-power frequency (six possible combinations). Thus, although differences between anterograde and retrograde atrial activity can be demonstrated in most patients, no single parameter displays sufficient discriminating power to facilitate physiologic pacing in patients exhibiting retrograde activity.     

自主神经阻滞后经食道心房调搏对老年人病窦诊断的价值

本文对30名健康老年人和12例老年病窦患者(年龄60～75岁)在自主神经阻滞(静注阿托品和心得安)前后作经食道心房调搏和固有心率(IHRo)测定,并与中年组作对照。结果发现:自主神经阻滞后测得的窦房结恢复时间和校正窦房结恢复时间对诊断老年人病窦的敏感性和准确性比阻滞前大大提高(敏感性由66.67%提高到100%,准确性由88.1%提高到97.63%),而特异性不变(均为96.7%)。用 IHRo/IHRp-2SD<1诊断老年人病赛的特异性达100%,准确度也高(85.71%),但敏感性较低(50%)。在老年人中应用自主神经阻滞方法安全可行。     

Therapeutic and Diagnostic Benefits of Intentional Crosstalk Mediated Ventricular Output Inhibition

Ventricular output inhibition due to crosstalk is generally considered unsafe and something that should be avoided. Special circuits have been incorporated in some dual chamber pacing systems to absolutely prevent this from happening. However, in patients with intact atrioventricular conduction, crosstalk mediated ventricular output inhibition can be beneficial to the evaluation and management of the patient. Utilizing this technique, one can achieve single chamber atrial paced rates which greatly exceed the rates allowed by lower rate limit programming to facilitate an assessment of the integrity of AV nodal conduction and to both convert and suppress some pathological tachyarrhythmias. The methods of achieving crosstalk and its utilization in four patients is discussed in this report.     

Long-Term Performance of Epimyocardial Pacing Leads in Adults: Comparison with Endocardial Leads

The long-term performance of epimyocardiaJ pacing leads in children is well established, but few studies have analyzed the performance in adults. This issue has clinical relevance in view of the increased use of epimyocardial leads with implantable cardioverter defibrillator and antitachycardia pacing systems. We analyzed 93 epimyocardial pacing "systems" (121 leads: 65 unipolar, 28 bipolar) in adult patients (age 57 ± 16 years), implanted since January 1980. Two different models were studied: Medtronic 4951 "Stab–on" (n = 35) and Medtronic 6917/6917A "Screw-in" (n = 58). A control group was created by randomly matching each epimyocardial system with two endocardial leads, according to age and year of implant. Epimyocardial and endocardial leads were followed-up for 44 ± 35 and 43 ± 35 months, respectively (P = NS). Freedom from failure for epimyocardial leads was 0.91 (95% Confidence Interval [95% CI] = 0.82 to 0.96) at 5 years, and 0.91 f95% CI = 0.69 to 0.98) at 10 years. No difference was found between the two analyzed models. Freedom from failure for endocardial leads was 0.97 (95% CI = 0.93 to 0.99) and 0.90 (95% CI = 0.61 to 0.97) at 5 and 10 years, respectively. Epimyocardial Jeads had a significantly poorer short-term survival than endocardiaJ leads, secondarily to earlier "technique related" failures (P = 0.03; relative riskc 3.0; Wilcoxon test). However, overall long-term performance was similar to endocardial leads. Epimyocardial pacing leads, meticulously implanted and tested, have a long-term performance similar to endocardial pacing leads.     

The interrelation between the monophasic action potential duration, cycle length and ischaemia in the human left ventricle.

Steady state monophasic action potentials were recorded from a single site in the left ventricular endocardium during incremental atrial pacing to the point of angina in 25 patients. Ischaemic areas of the left ventricle were documented using a perfusion marker (99mTc-MIBI) simultaneously with the action potential recording procedure. Recordings were obtained from an ischaemic area in 13 patients and from a non-ischaemic area in 12. A linear correlation between action potential duration and cycle length changes was demonstrated for both ischaemic and non-ischaemic zone recordings between cycle length changes of 750 and 428 ms. Ischaemia induced a shortening of the action potential duration significantly greater than that produced by cycle length changes (P less than 0.0001). Mean action potential duration shortening corrected for 100 ms change in cycle length for ischaemic zone recordings was 31.4 +/- 4.2 (SD) compared to 23.3 +/- 3.1 ms for non-ischaemic zone recordings. A range of values of action potential duration shortening in unit time was analysed for sensitivity and specificity for the detection of ischaemia. A value of 26.5 ms per 100 ms change in cycle length provided the optimum compromise with 88% sensitivity and specificity. Our data provide a means of employing the monophasic action potential duration to quantify early localized ischaemia in the presence of an alteration in cycle length.     

Safety and Efficacy of Pacing for Ventricular Tachycardia

This study was undertaken to determine the safety and efficacy of three different pacing modalities on the termination of ventricular tachyarrhythmias. Thirty-two patients were studied in the electrophysiology laboratory. Three randomized pacing modalities were selected for attempted conversion: auto increment, auto burst, and random burst. In all three groups, arrhythmias with cycle lengths shorter than 230 ms required DC shock, with one exception. Those longer than 230 ms were terminated by pacing in 85% of cases. There was a 15% rate of acceleration. Thus, antitachycardia pacing for ventricular tachyarrhythmias should be considered only with defibrillating back-up.